Has Cochrane lost its way?

  title={Has Cochrane lost its way?},
  author={Melanie Newman},
  journal={British Medical Journal},
  • M. Newman
  • Published 3 January 2019
  • Art
  • British Medical Journal
Dissent over growing centralisation culminated in the expulsion of one of Cochrane’s founding members. Melanie Newman reports on the organisation’s internal struggles 

Clarification of News Feature “Has Cochrane lost its way?”

Tovey claims that the statement in my piece that Cochrane guidance “still allows reviewers to review their own studies” is an “error” and that Cochrane guidance does not allow this.12 He says,

Cochrane has not consistently followed the COPE guidelines

  • H. Hemilä
  • Education
    European journal of clinical investigation
  • 2020
There have been concerns about the procedures and policies of the Cochrane organization. Here I describe one case where Cochrane procedures seemed inconsistent with the Committee on Publication

David Tovey replies to Melanie Newman and The BMJ

Newman asks whether Cochrane has “lost its way” given recent ructions arising from the governing board’s decision to remove membership status from Peter Gotzsche.1 On the contrary, by all objective

Quo Vadis, Cochrane Collaboration?

  • A. Jokstad
  • Political Science
    Clinical and experimental dental research
  • 2019
It seems to undersigned that this initially idealistic charity has contracted some form of Icarus syndrome prompted by seduction to generate substantial revenues rather than strengthening the actual value of the offered products.

Expelled Cochrane director to set up new institute for “integrity in science”

  • M. Newman
  • Political Science
    British Medical Journal
  • 2019
The expelled member of Cochrane’s board Peter Gotzsche plans to found a new Institute for Scientific Freedom, which will focus on lobbying for improvements in healthcare research quality as well as producing its own research.



New CEO transforming The Cochrane Collaboration

The Cochrane Collaboration offices are small; standing outside their modestly sized single-floor office makes you wonder just how they wield such clout.


  • A. Bussu
  • Law
    Police Practice and Research
  • 2018
In this first Issue of 2019, we have decided to publish together several book reviews which are contributions to the IPES Book Series, Interviews with Global Leaders in Policing, Court and

Cochrane at crossroads over drug company sponsorship

  • R. Moynihan
  • Political Science
    BMJ : British Medical Journal
  • 2003
The Cochrane Collaboration is at a crossroads, with its supporters deeply divided over whether to embrace drug company sponsorship, and delegates to its annual colloquium next week will debate the thorny question of conflict of interest.

New Cochrane policy tightens limits on industry funding

  • J. Lenzer
  • Medicine
    BMJ : British Medical Journal
  • 2004
A year long struggle over funding of the Cochrane Collaboration has been settled: a policy just issued by the organisation will limit industry funding, reflecting the overwhelming consensus of members.

Neuraminidase inhibitors—the story behind the Cochrane review

  • P. Doshi
  • Medicine
    BMJ : British Medical Journal
  • 2009
Although billions have been spent on oseltamivir in the face of pandemic influenza, the team updating the Cochrane review of neuraminidase inhibitors in healthy adults found that the public evidence

Evidence-based medicine and the Cochrane Collaboration on trial.

  • D. Cundiff
  • Medicine
    MedGenMed : Medscape general medicine
  • 2007
The Cochrane Collaboration was founded in 1993 and was named for the British epidemiologist Archie Cochrane, MD (1908-1988), who suggested that the free care in the National Health Service should be limited to interventions supported by evidence of their effectiveness.

Research synthesis and dissemination as a bridge to knowledge management: the Cochrane Collaboration.

The work of the Cochrane Collaboration is set in historical perspective, what a Cochrane review is, initiatives for promoting worldwide dissemination of synthesized information are described, and the need for increased investment in the preparation and maintenance of Cochrane reviews is highlighted.

Quality of Cochrane reviews: assessment of sample from 1998

Too often, reviewers' conclusions over-rated the benefits of new interventions and readers of Cochrane reviews should remain cautious, especially regarding conclusions that favour new interventions.

Deadly Medicines and Organised Crime

Busting the industry myths, the business model of big pharma, Psychiatrists as drug pushers and more lies about happy pills are revealed.